NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 181)
Posted On: 08/14/2020 3:44:19 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Q2 2020 Results, Business Update and DojoLIVE! Interview
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Thursday released financial results for the quarter ended June 30, 2020 and provided a business update. “During the second quarter we reached a major milestone in our journey towards full commercialization with the first sale of our novel ovarian cancer cell media to a top-rated medical university in New England,” Dr. Carl Schwartz, Predictive Oncology CEO, stated in the news release. “This sale serves as a solid proof point of our mission and is a significant achievement towards improving healthcare outcomes for cancer patients. Our unique media significantly expands the number of ovarian cancer cell types that can be studied representing nearly 95% of all ovarian cancers, many of which have never been cultured before now, and reduces waste in cancer research.”
In addition, the company today announced that Mark Collins, Ph.D., chief innovation officer of its Helomics subsidiary, recently appeared on DojoLIVE!, an engaging podcast and interview forum that brings together technology, business and thought leaders from a wide range of software companies and startups. The broadcast is titled “Can We Cure Cancer With Artificial Intelligence?” and is available via the DojoLIVE! website for on-demand viewing. During the interview, Collins discussed a passion for applying science to build high-tech products and services that impact the search for new medicines and the unique positioning of Helomics to deliver on this goal.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Thursday released financial results for the quarter ended June 30, 2020 and provided a business update. “During the second quarter we reached a major milestone in our journey towards full commercialization with the first sale of our novel ovarian cancer cell media to a top-rated medical university in New England,” Dr. Carl Schwartz, Predictive Oncology CEO, stated in the news release. “This sale serves as a solid proof point of our mission and is a significant achievement towards improving healthcare outcomes for cancer patients. Our unique media significantly expands the number of ovarian cancer cell types that can be studied representing nearly 95% of all ovarian cancers, many of which have never been cultured before now, and reduces waste in cancer research.”
In addition, the company today announced that Mark Collins, Ph.D., chief innovation officer of its Helomics subsidiary, recently appeared on DojoLIVE!, an engaging podcast and interview forum that brings together technology, business and thought leaders from a wide range of software companies and startups. The broadcast is titled “Can We Cure Cancer With Artificial Intelligence?” and is available via the DojoLIVE! website for on-demand viewing. During the interview, Collins discussed a passion for applying science to build high-tech products and services that impact the search for new medicines and the unique positioning of Helomics to deliver on this goal.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)